期刊文献+

4-取代-7-氯喹啉衍生物的合成及抗肿瘤活性的初步评价 被引量:1

Synthesis of 4-substituted-7-chloroquinoline derivatives and preliminary evaluation of their antitumor activity
原文传递
导出
摘要 目的:设计合成一系列4-取代-7-氯喹啉衍生物并测定其抗肿瘤活性。方法:4,7-二氯喹啉通过烃化反应及缩合反应得到目标化合物,并采用MTT法,评价了其对4种体外培养肿瘤细胞的生长抑制作用。结果:大多数化合物具有一定的抑制肿瘤细胞增殖的活性,其中化合物3,5和10a抑制人非小细胞肺癌A549,NCI-H446,Hela细胞生长的作用强于阳性对照,化合物5和10a对于人非小细胞肺癌A549的抑制活性是阳性对照药的4~5倍,明显优于阳性对照。结论:本文合成的该系列部分化合物具有较好的抗肿瘤活性,是潜在的抗肿瘤候选药物。 Objective: To design and synthesize a series of 4-substituted-7-chloroquinoline derivatives, and to assay their antitumor activity. Methods: The compounds were synthesized through alkylation and condensation reaction using 4,7-dichloro-quinoline, and the antitumor activities were assayed by MTT. Results: Most synthe- sized compounds had the property of antiproliferation on tumor cell lines in vitro. It was obvious that the compounds of 3,5 and 10a had stronger effect on the growth of A549, NCI-H446 and Hela cancer cells than the positive con- trol group does, and compounds 5 and 10a also showed 4 - 5 times more inhibition effect on the A549 cells than the positive control group in terms of antitumor activity. Conclusion: The series of synthesized compounds exhibit ex- cellent antitumor activities and deserve consideration for potential candidate of antitumor drugs
出处 《中国新药杂志》 CAS CSCD 北大核心 2014年第5期585-590,600,共7页 Chinese Journal of New Drugs
基金 泉州市科技计划重点项目(2013Z35)
关键词 4-取代-7-氯喹啉衍生物 酪氨酸激酶 MTT 肿瘤 4-subtituted-7-chloroquinoline derivatives tyrosine kinase MTT tumor
  • 相关文献

参考文献9

  • 1PAWSON T. Regulation and targets of receptor tyrosine kinases[J]. Eur J Cancer, 2002 , 38 ( Suppl 5 ) : S3 - S10.
  • 2秦爱方,李燕,宋宏锐,陈晓光,金小锋,王克,张莉婧,霍连超,冯志强.含吡啶-2-酰肼结构的索拉非尼类似物的设计、合成及其抗肿瘤活性[J].药学学报,2012,47(12):1623-1629. 被引量:5
  • 3孙忠实,朱珠,韩风英.酪氨酸激酶抑制剂——伊马替尼[J].中国药学杂志,2003,38(1):69-71. 被引量:24
  • 4NG KP, HILLMER AM, CHUAH CTH, et al. A common BIMdeletion polymorphism mediates intrinsic resistance and inferiorresponses to tyrosine kinase inhibitors in cancer [ J] . Nat Med,2012, 4(18) :521 -528.
  • 5GRUNDSCHOBER E , WARSCH W, SEXL V. The transcriptionfactor STAT5 drives mutation and imatinib resistance in chronicmyeloid leukemia via ROS production [ J]. BMC Pharmacol,2011 , 11 ( Suppl 2) ;A22.
  • 6史玉叶,李玉峰.慢性粒细胞白血病耐伊马替尼机制及治疗进展[J].现代医学,2011,39(6):751-753. 被引量:5
  • 7WEICKHARDT AJ, TEBBUTT NC, MARIADASON JM. Strate-gies for overcoming inherent and acquired resistance to EGFR in-hibitors by targeting downstream effectors in the RAS/PI3K path-way [J]. Curr Cancer Drug Tar, 2010, 10(8):824 -833.
  • 8JANMAAT ML, KRUYT FAE, RODRIGUEZ JA, el al. Re-sponse to epidermal growth factor receptor inhibitors in nonsmallcell lung cancer cells : limited antiproliferative effects and ab-sence of apoptosis associated with persistent activity of extracellu-lar signal-regulated kinase or Akt kinase pathways [ J]. ClinCancer Res,2003, 9(6) :2316 -2326.
  • 9MOON DO, KIM MO , HEO MS, et al. Gefitinib induces apop-tosis and decreases telomerase activity in MDA-MB-231 humanbreast cancer cells[ J] . Arch Pharm Res, 2009 , 32 ( 10) ; 1351 -1360.

二级参考文献6

  • 1SENGUPTA A, BANERJEE D, CHANDRA S, et al. Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling in chronic myeloid leukemia progression[ J]. Leukemia,2007,21 (5) :949-955.
  • 2KRAUSE D S, LAZARIDES K, yon ANDRIAN U H, et al. Requirement for CD44 in homing and engraftment of BCR- ABL- expressing leukemic stem cells [ J ]. Nat Med, 2006, 12:1175-1180.
  • 3ESSERS M A, OFFNER S, BLANCO-BOSE W E, et al. IF-Nalpha activates dormant haematopoietic stem cells in vivo [ J ]. Nature,2009,458:904- 908.
  • 4BURCHERERT A, MULLER M C, KOSTREWA P, et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia [ J ]. J Clin Oncol, 2010,28 : 1429-1435.
  • 5茆勇军,李海泓,李剑峰,沈敬山.蛋白酪氨酸激酶信号转导途径与抗肿瘤药物[J].药学学报,2008,43(4):323-334. 被引量:50
  • 6张浩,邵荣光.G3BP:一个潜在的肿瘤治疗靶点[J].药学学报,2010,45(8):945-951. 被引量:8

共引文献31

同被引文献9

  • 1PAO W,MILLER V A,POLITI K A,et al.Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain[J].PLOS Med,2005,2(3):e73.
  • 2DONG Song,ZHANG Xu-chao,CHENG Hua,et al.Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors[J].Cancer Chemoth Pharm,2012,70(5):707-716.
  • 3LA M S,GALETTI M,ALFIERI R R,et al.Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines[J].Biochem Pharmaco,2009,78(5):460-468.
  • 4MUKOHARA T,ENGELMAN J A,HANNA N H,et al.Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearingepidermal growth factor receptor mutations[J].J Natl Cancer Inst,2005,97(16): 1185-1194.
  • 5HYNES N E,LANE H A.ERBB receptors and cancer: The complexity of targeted inhibitors[J].Nat Rev Cancer,2005,5(5):341-354.
  • 6RECK M,van ZANDWIJK N,GRIDELLI C,et al.Erlotinib in advancednon-small cell lung cancer: Efficacy and safety findings of the global phase Ⅳ tarceva lung cancer survival treatment study[J].J Thorac Oncol,2010,5(10):1616-1622.
  • 7PEDERSEN M W,PEDERSEN N,OTTESEN L H,et al.Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII[J].Br J Cancer,2005,93(8):915-923.
  • 8TISEO M,ROSSI G,CAPELLETTI M,et al.Predictors of gefitinib outcomes in advanced non-small cell lung cancer(NSCLC): Study of a comprehensive panel of molecular markers[J].Lung Cancer,2010,67(3):355-360.
  • 9DANCEY J E.Agents targeting ras signaling pathway[J].Curr Pharm Des,2002,8(25):2259-2267.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部